Literature DB >> 23752365

Bone metastases: assessment, management and treatment options.

Carole Farrell1.   

Abstract

Cancer cells from a primary tumour can spread to other parts of the body through the bloodstream or the lymphatic system. Bone metastases are common in multiple myeloma, where 70-80% of patients have bone metastases at diagnosis. They are also a common feature in solid tumours such as breast, lung, prostate, thyroid and renal carcinomas. The median survival in patients with bone metastases from breast cancer is 24 months; 20% of patients survive for 5 years or more. Pain is the most common symptom of bone metastases, which can often be severe and difficult to control. This article will discuss normal bone physiology and explain the changes that occur when cancer cells spread to bone. It will outline the signs and symptoms of bone metastases and discuss patient assessment, symptom management and treatment options, including different bisphosphonates. The physical and psychological impact of bone metastases should not be underestimated and nurses are well placed to improve the quality of life of patients.

Entities:  

Mesh:

Year:  2013        PMID: 23752365     DOI: 10.12968/bjon.2013.22.Sup7.S4

Source DB:  PubMed          Journal:  Br J Nurs        ISSN: 0966-0461


  4 in total

1.  NGF blockade at early times during bone cancer development attenuates bone destruction and increases limb use.

Authors:  Gwen McCaffrey; Michelle L Thompson; Lisa Majuta; Michelle N Fealk; Stephane Chartier; Geraldine Longo; Patrick W Mantyh
Journal:  Cancer Res       Date:  2014-10-06       Impact factor: 12.701

2.  Clinicopathologic characteristics and survival of patients with bone metastasis in Yazd, Iran: a cross-sectional retrospective study.

Authors:  Masood Shabani; Fariba Binesh; Nasim Behniafard; Faezeh Nasiri; Farimah Shamsi
Journal:  Medicine (Baltimore)       Date:  2014-12       Impact factor: 1.889

Review 3.  AAPT Diagnostic Criteria for Chronic Cancer Pain Conditions.

Authors:  Judith A Paice; Matt Mulvey; Michael Bennett; Patrick M Dougherty; John T Farrar; Patrick W Mantyh; Christine Miaskowski; Brian Schmidt; Thomas J Smith
Journal:  J Pain       Date:  2016-11-21       Impact factor: 5.820

4.  Effects of Artonin E on Cell Growth Inhibition and Apoptosis Induction in Colon Cancer LoVo and HCT116 Cells.

Authors:  Kanyaluck Yangnok; Sukanda Innajak; Ratchawin Sawasjirakij; Wilawan Mahabusarakam; Ramida Watanapokasin
Journal:  Molecules       Date:  2022-03-24       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.